25 XP   0   0   10

Pacira Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Pacira together

PenkeI guess you are interested in Pacira Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Pacira Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Pacira Pharmaceuticals Inc

I send you an email if I find something interesting about Pacira Pharmaceuticals Inc.

Quick analysis of Pacira (30 sec.)










What can you expect buying and holding a share of Pacira? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
$16.71
Expected worth in 1 year
$16.76
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
$0.05
Return On Investment
0.2%

For what price can you sell your share?

Current Price per Share
$26.10
Expected price per share
$25.93 - $27.89
How sure are you?
50%

1. Valuation of Pacira (5 min.)




Live pricePrice per Share (EOD)

$26.10

Intrinsic Value Per Share

$15.95 - $38.04

Total Value Per Share

$32.66 - $54.75

2. Growth of Pacira (5 min.)




Is Pacira growing?

Current yearPrevious yearGrowGrow %
How rich?$870.1m$752.8m$66.5m8.1%

How much money is Pacira making?

Current yearPrevious yearGrowGrow %
Making money$10.4m$3.9m$6.5m62.1%
Net Profit Margin5.8%2.4%--

How much money comes from the company's main activities?

3. Financial Health of Pacira (5 min.)




What can you expect buying and holding a share of Pacira? (5 min.)

Welcome investor! Pacira's management wants to use your money to grow the business. In return you get a share of Pacira.

What can you expect buying and holding a share of Pacira?

First you should know what it really means to hold a share of Pacira. And how you can make/lose money.

Speculation

The Price per Share of Pacira is $26.10. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Pacira.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Pacira, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $16.71. Based on the TTM, the Book Value Change Per Share is $0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $0.24 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Pacira.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.481.8%0.190.7%0.070.3%0.240.9%0.070.3%
Usd Book Value Change Per Share0.742.8%0.010.0%0.240.9%0.491.9%0.401.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.010.0%0.000.0%
Usd Total Gains Per Share0.742.8%0.010.0%0.240.9%0.501.9%0.401.5%
Usd Price Per Share33.74-36.33-56.61-49.48-52.49-
Price to Earnings Ratio17.66-12.60--192.07--41.98-2,525.62-
Price-to-Total Gains Ratio45.48--49.69-38.13-86.73-94.87-
Price to Book Ratio2.02-2.25-3.64-4.11-10.17-
Price-to-Total Gains Ratio45.48--49.69-38.13-86.73-94.87-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share26.1
Number of shares38
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share0.010.49
Usd Total Gains Per Share0.010.50
Gains per Quarter (38 shares)0.4418.98
Gains per Year (38 shares)1.7575.92
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
102-817566
204-63149142
305-44224218
407-26298294
50907373370
601128447446
7012410522522
8014611596598
9016813671674
100181014745750

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%8.04.00.066.7%12.08.00.060.0%19.021.00.047.5%19.039.01.032.2%
Book Value Change Per Share2.02.00.050.0%8.04.00.066.7%16.04.00.080.0%32.08.00.080.0%37.020.02.062.7%
Dividend per Share0.00.04.00.0%2.00.010.016.7%4.00.016.020.0%4.00.036.010.0%4.00.055.06.8%
Total Gains per Share2.02.00.050.0%8.04.00.066.7%16.04.00.080.0%32.08.00.080.0%37.020.02.062.7%

Fundamentals of Pacira

About Pacira Pharmaceuticals Inc

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Fundamental data was last updated by Penke on 2024-04-12 14:43:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Pacira Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Pacira earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Pacira to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 13.7% means that $0.14 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Pacira Pharmaceuticals Inc:

  • The MRQ is 13.7%. The company is making a huge profit. +2
  • The TTM is 5.8%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ13.7%TTM5.8%+7.9%
TTM5.8%YOY2.4%+3.4%
TTM5.8%5Y8.8%-3.0%
5Y8.8%10Y0.5%+8.3%
1.1.2. Return on Assets

Shows how efficient Pacira is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Pacira to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.6% Return on Assets means that Pacira generated $0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Pacira Pharmaceuticals Inc:

  • The MRQ is 1.6%. Using its assets, the company is less efficient in making profit.
  • The TTM is 0.7%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.6%TTM0.7%+0.9%
TTM0.7%YOY0.2%+0.5%
TTM0.7%5Y0.9%-0.2%
5Y0.9%10Y-0.2%+1.0%
1.1.3. Return on Equity

Shows how efficient Pacira is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Pacira to the Drug Manufacturers - Specialty & Generic industry mean.
  • 2.9% Return on Equity means Pacira generated $0.03 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Pacira Pharmaceuticals Inc:

  • The MRQ is 2.9%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.2%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.9%TTM1.2%+1.7%
TTM1.2%YOY0.5%+0.7%
TTM1.2%5Y1.7%-0.5%
5Y1.7%10Y-0.8%+2.5%

1.2. Operating Efficiency of Pacira Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Pacira is operating .

  • Measures how much profit Pacira makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Pacira to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 18.7% means the company generated $0.19  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Pacira Pharmaceuticals Inc:

  • The MRQ is 18.7%. The company is operating efficient. +1
  • The TTM is 13.9%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ18.7%TTM13.9%+4.9%
TTM13.9%YOY8.7%+5.1%
TTM13.9%5Y13.2%+0.6%
5Y13.2%10Y4.5%+8.8%
1.2.2. Operating Ratio

Measures how efficient Pacira is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.81 means that the operating costs are $0.81 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Pacira Pharmaceuticals Inc:

  • The MRQ is 0.813. The company is less efficient in keeping operating costs low.
  • The TTM is 0.873. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.813TTM0.873-0.060
TTM0.873YOY0.893-0.020
TTM0.8735Y0.870+0.002
5Y0.87010Y0.951-0.081

1.3. Liquidity of Pacira Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Pacira is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 5.24 means the company has $5.24 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Pacira Pharmaceuticals Inc:

  • The MRQ is 5.237. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.441. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.237TTM4.441+0.796
TTM4.441YOY3.391+1.050
TTM4.4415Y4.318+0.123
5Y4.31810Y4.352-0.033
1.3.2. Quick Ratio

Measures if Pacira is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Pacira to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 5.23 means the company can pay off $5.23 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Pacira Pharmaceuticals Inc:

  • The MRQ is 5.231. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.627. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.231TTM4.627+0.604
TTM4.627YOY3.947+0.680
TTM4.6275Y5.610-0.984
5Y5.61010Y5.982-0.371

1.4. Solvency of Pacira Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Pacira assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Pacira to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.45 means that Pacira assets are financed with 44.7% credit (debt) and the remaining percentage (100% - 44.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Pacira Pharmaceuticals Inc:

  • The MRQ is 0.447. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.469. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.447TTM0.469-0.022
TTM0.469YOY0.571-0.102
TTM0.4695Y0.532-0.063
5Y0.53210Y0.520+0.012
1.4.2. Debt to Equity Ratio

Measures if Pacira is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Pacira to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 80.9% means that company has $0.81 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Pacira Pharmaceuticals Inc:

  • The MRQ is 0.809. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.887. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.809TTM0.887-0.077
TTM0.887YOY1.345-0.458
TTM0.8875Y1.165-0.279
5Y1.16510Y1.146+0.020

2. Market Valuation of Pacira Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Pacira generates.

  • Above 15 is considered overpriced but always compare Pacira to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 17.66 means the investor is paying $17.66 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Pacira Pharmaceuticals Inc:

  • The EOD is 13.660. Based on the earnings, the company is underpriced. +1
  • The MRQ is 17.658. Based on the earnings, the company is fair priced.
  • The TTM is 12.598. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD13.660MRQ17.658-3.998
MRQ17.658TTM12.598+5.060
TTM12.598YOY-192.070+204.669
TTM12.5985Y-41.981+54.579
5Y-41.98110Y2,525.619-2,567.600
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Pacira Pharmaceuticals Inc:

  • The EOD is 7.420. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 9.592. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 17.523. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD7.420MRQ9.592-2.172
MRQ9.592TTM17.523-7.931
TTM17.523YOY27.376-9.853
TTM17.5235Y-45.245+62.768
5Y-45.24510Y-26.264-18.981
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Pacira is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Pacira Pharmaceuticals Inc:

  • The EOD is 1.562. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.019. Based on the equity, the company is underpriced. +1
  • The TTM is 2.248. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.562MRQ2.019-0.457
MRQ2.019TTM2.248-0.229
TTM2.248YOY3.643-1.395
TTM2.2485Y4.112-1.864
5Y4.11210Y10.172-6.061
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Pacira Pharmaceuticals Inc.

3.1. Institutions holding Pacira Pharmaceuticals Inc

Institutions are holding 107.779% of the shares of Pacira Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc17.44970.00781142516072548.0892
2023-12-31Vanguard Group Inc10.96420.003850984241417192.8591
2023-12-31Frontier Capital Management CO Inc4.48280.7104208454228504515.8403
2023-12-31State Street Corporation4.16370.003219361581509198.4537
2023-12-31Renaissance Technologies Corp3.69180.089717166971027006.3631
2023-12-31Dimensional Fund Advisors, Inc.3.0360.01391411767179491.2878
2023-12-31Macquarie Group Ltd2.97660.0541384163-277750-16.7127
2023-12-31Stephens Inv Mgmt Group LLC2.83440.65011318005-25659-1.9096
2023-12-31Vestal Point Capital LP2.58064.2892120000012000000
2023-12-31ClearBridge Advisors, LLC2.46380.03331145687-3788-0.3295
2023-12-31Baillie Gifford & Co Limited.2.28660.02841063266-573810-35.0509
2023-12-31Rock Springs Capital Management LP2.26990.8767105550000
2023-12-31Pacer Advisors, INC.2.24010.099510416791041417397487.4046
2023-12-31Rice Hall James & Associates, LLC2.22792.02411035969674846.968
2023-12-31Geode Capital Management, LLC2.15830.00351003617472404.9395
2023-12-31Morgan Stanley - Brokerage Accounts1.47380.00268533422401148.5584
2023-12-31Schroder Investment Management Group1.3370.0272621709-45919-6.8779
2023-12-31HHG PLC1.2990.01226040336633012.3358
2023-12-31Gagnon Securities LLC1.17334.4187545579-19850-3.5106
2023-12-31Northern Trust Corp1.1360.0032528261245994.884
Total 72.245513.350133594641+3029891+9.0%

3.2. Funds holding Pacira Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-28iShares Core S&P Small-Cap ETF6.74570.11413136782-11608-0.3687
2024-03-28Pacer US Small Cap Cash Cows 100 ETF3.37980.472157163255580.3549
2024-02-29Vanguard Total Stock Mkt Idx Inv2.97330.00271382626-15054-1.0771
2024-02-29Delaware Small Cap Core I2.7880.52341296449441143.5225
2024-02-29Vanguard Small Cap Index2.44530.0241137064104920.9313
2024-03-28iShares Russell 2000 ETF2.40940.0511204045400.0482
2023-12-31Macquarie US Small Cap Core Equity2.39520.5028111379222575625.4219
2023-12-31ClearBridge Small Cap Growth A1.95660.7368909815-10124-1.1005
2024-02-29ClearBridge Small Cap Growth1.93690.653690069300
2023-12-31Stephens SMID Select Growth1.7030.665791901-23479-2.8795
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.46330.01986804454660.0685
2023-12-31Vanguard Explorer Inv1.4060.103265382060200.9293
2024-02-29Vanguard Small Cap Growth Index Inv1.37250.0544638241106031.6893
2024-03-28iShares S&P Small-Cap 600 Value ETF1.23020.2314572069-5719-0.9898
2023-12-31Janus Henderson Small Cap Value L1.20710.75735613216933814.0936
2024-01-31Fidelity Small Cap Index0.99060.060646065868181.5023
2023-12-31HBM Healthcare Investments AG Ord0.97060.762745132400
2023-12-31Stephens Small Cap Growth0.93660.7915435541-250-0.0574
2024-03-28SPDR® Portfolio S&P 600 Sm Cap ETF0.89550.11574164134200.101
2024-03-28iShares Russell 2000 Growth ETF0.84780.0988394211-458-0.116
Total 40.05346.739818625201+313433+1.7%

3.3. Insider Transactions

Insiders are holding 1.242% of the shares of Pacira Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-08Gary W PaceSELL9000030.6
2024-03-06Gary W PaceSELL106629.67
2023-08-02Roy WinstonSELL50934.88
2023-07-05Lauren Bullaro RikerSELL64338.91
2023-06-14Kristen Marie WilliamsSELL646737.03
2023-06-14Lauren Bullaro RikerSELL636638.42
2023-06-08Mark A KronenfeldSELL1500037.04
2023-06-07Daryl GauglerSELL104737.87
2023-06-06Charles A Reinhart IiiSELL123638.99
2023-06-06David M StackSELL505838.99
2023-06-06Lauren Bullaro RikerSELL59138.99
2023-06-06Roy WinstonSELL177938.99
2023-06-05Daryl GauglerSELL100038.74
2023-06-05Paul J HastingsSELL58038.34
2023-05-31Daryl GauglerSELL250039.08
2023-05-11Gary W PaceSELL501541.78

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Pacira Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.7420.012+6337%0.240+209%0.490+51%0.396+88%
Book Value Per Share--16.71316.181+3%15.726+6%12.966+29%8.887+88%
Current Ratio--5.2374.441+18%3.391+54%4.318+21%4.352+20%
Debt To Asset Ratio--0.4470.469-5%0.571-22%0.532-16%0.520-14%
Debt To Equity Ratio--0.8090.887-9%1.345-40%1.165-31%1.146-29%
Dividend Per Share----0%-0%0.009-100%0.005-100%
Eps--0.4780.190+151%0.073+551%0.242+97%0.071+570%
Free Cash Flow Per Share--0.8790.677+30%0.608+45%0.450+95%0.243+262%
Free Cash Flow To Equity Per Share--0.845-0.290+134%-1.456+272%0.496+70%0.465+82%
Gross Profit Margin---0.437-0.072-84%12.179-104%3.495-113%-57.686+13101%
Intrinsic Value_10Y_max--38.037--------
Intrinsic Value_10Y_min--15.952--------
Intrinsic Value_1Y_max--2.510--------
Intrinsic Value_1Y_min--1.084--------
Intrinsic Value_3Y_max--8.535--------
Intrinsic Value_3Y_min--3.723--------
Intrinsic Value_5Y_max--15.754--------
Intrinsic Value_5Y_min--6.850--------
Market Cap1213670880.000-45%1756639360.0001834389087.000-4%2719295474.000-35%2347193125.000-25%2463982137.300-29%
Net Profit Margin--0.1370.058+135%0.024+462%0.088+56%0.005+2495%
Operating Margin--0.1870.139+35%0.087+115%0.132+41%0.045+318%
Operating Ratio--0.8130.873-7%0.893-9%0.870-7%0.951-15%
Pb Ratio1.562-29%2.0192.248-10%3.643-45%4.112-51%10.172-80%
Pe Ratio13.660-29%17.65812.598+40%-192.070+1188%-41.981+338%2525.619-99%
Price Per Share26.100-29%33.74036.325-7%56.605-40%49.477-32%52.488-36%
Price To Free Cash Flow Ratio7.420-29%9.59217.523-45%27.376-65%-45.245+572%-26.264+374%
Price To Total Gains Ratio35.179-29%45.477-49.691+209%38.135+19%86.725-48%94.865-52%
Quick Ratio--5.2314.627+13%3.947+33%5.610-7%5.982-13%
Return On Assets--0.0160.007+136%0.002+629%0.009+81%-0.002+111%
Return On Equity--0.0290.012+138%0.005+421%0.017+64%-0.008+128%
Total Gains Per Share--0.7420.012+6337%0.240+209%0.499+49%0.400+85%
Usd Book Value--870130000.000819424250.000+6%752836250.000+16%620643800.000+40%422115325.000+106%
Usd Book Value Change Per Share--0.7420.012+6337%0.240+209%0.490+51%0.396+88%
Usd Book Value Per Share--16.71316.181+3%15.726+6%12.966+29%8.887+88%
Usd Dividend Per Share----0%-0%0.009-100%0.005-100%
Usd Eps--0.4780.190+151%0.073+551%0.242+97%0.071+570%
Usd Free Cash Flow--45786000.00034872000.000+31%28799500.000+59%21706450.000+111%11676350.000+292%
Usd Free Cash Flow Per Share--0.8790.677+30%0.608+45%0.450+95%0.243+262%
Usd Free Cash Flow To Equity Per Share--0.845-0.290+134%-1.456+272%0.496+70%0.465+82%
Usd Market Cap1213670880.000-45%1756639360.0001834389087.000-4%2719295474.000-35%2347193125.000-25%2463982137.300-29%
Usd Price Per Share26.100-29%33.74036.325-7%56.605-40%49.477-32%52.488-36%
Usd Profit--24870000.00010488750.000+137%3977250.000+525%11717600.000+112%3536525.000+603%
Usd Revenue--181244000.000168744500.000+7%166705750.000+9%136579050.000+33%101963100.000+78%
Usd Total Gains Per Share--0.7420.012+6337%0.240+209%0.499+49%0.400+85%
 EOD+4 -4MRQTTM+29 -5YOY+29 -55Y+26 -1010Y+28 -8

4.2. Fundamental Score

Let's check the fundamental score of Pacira Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1513.660
Price to Book Ratio (EOD)Between0-11.562
Net Profit Margin (MRQ)Greater than00.137
Operating Margin (MRQ)Greater than00.187
Quick Ratio (MRQ)Greater than15.231
Current Ratio (MRQ)Greater than15.237
Debt to Asset Ratio (MRQ)Less than10.447
Debt to Equity Ratio (MRQ)Less than10.809
Return on Equity (MRQ)Greater than0.150.029
Return on Assets (MRQ)Greater than0.050.016
Total7/10 (70.0%)

4.3. Technical Score

Let's check the technical score of Pacira Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5030.635
Ma 20Greater thanMa 5028.124
Ma 50Greater thanMa 10029.048
Ma 100Greater thanMa 20030.101
OpenGreater thanClose26.790
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -380243-137-36-173163-10257247
Net Interest Income  -8,2561,809-6,4474,693-1,7541,056-69873537



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,574,386
Total Liabilities704,256
Total Stockholder Equity870,130
 As reported
Total Liabilities 704,256
Total Stockholder Equity+ 870,130
Total Assets = 1,574,386

Assets

Total Assets1,574,386
Total Current Assets509,994
Long-term Assets1,064,392
Total Current Assets
Cash And Cash Equivalents 153,298
Short-term Investments 125,283
Net Receivables 105,556
Inventory 104,353
Other Current Assets 21,504
Total Current Assets  (as reported)509,994
Total Current Assets  (calculated)509,994
+/-0
Long-term Assets
Property Plant Equipment 234,947
Goodwill 163,243
Long Term Investments 2,410
Intangible Assets 483,258
Long-term Assets Other 36,049
Long-term Assets  (as reported)1,064,392
Long-term Assets  (calculated)919,907
+/- 144,485

Liabilities & Shareholders' Equity

Total Current Liabilities97,383
Long-term Liabilities606,873
Total Stockholder Equity870,130
Total Current Liabilities
Short-term Debt 17,442
Short Long Term Debt 8,641
Accounts payable 15,698
Other Current Liabilities 64,243
Total Current Liabilities  (as reported)97,383
Total Current Liabilities  (calculated)106,024
+/- 8,641
Long-term Liabilities
Long term Debt 513,796
Capital Lease Obligations Min Short Term Debt46,165
Long-term Liabilities Other 38,271
Long-term Liabilities  (as reported)606,873
Long-term Liabilities  (calculated)598,232
+/- 8,641
Total Stockholder Equity
Common Stock46
Retained Earnings -106,796
Accumulated Other Comprehensive Income 247
Other Stockholders Equity 976,633
Total Stockholder Equity (as reported)870,130
Total Stockholder Equity (calculated)870,130
+/-0
Other
Capital Stock46
Cash and Short Term Investments 278,581
Common Stock Shares Outstanding 52,064
Liabilities and Stockholders Equity 1,574,386
Net Debt 432,746
Net Invested Capital 1,392,567
Net Working Capital 412,611
Property Plant and Equipment Gross 370,253
Short Long Term Debt Total 586,044



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302008-12-31
> Total Assets 
50,541
0
43,954
0
50,240
52,756
66,562
97,869
87,092
77,609
113,490
94,264
142,853
132,826
112,054
185,241
178,430
172,395
169,820
163,693
292,080
305,394
326,072
335,030
354,993
368,988
389,623
391,206
400,699
381,153
391,466
599,962
605,745
606,090
628,371
622,037
642,681
659,045
689,353
719,156
787,843
807,489
831,065
821,379
866,111
1,220,269
1,274,513
1,287,549
1,325,833
1,356,002
2,075,353
1,891,476
1,733,988
1,734,365
1,681,200
1,523,418
1,542,381
1,534,462
1,574,386
1,574,3861,534,4621,542,3811,523,4181,681,2001,734,3651,733,9881,891,4762,075,3531,356,0021,325,8331,287,5491,274,5131,220,269866,111821,379831,065807,489787,843719,156689,353659,045642,681622,037628,371606,090605,745599,962391,466381,153400,699391,206389,623368,988354,993335,030326,072305,394292,080163,693169,820172,395178,430185,241112,054132,826142,85394,264113,49077,60987,09297,86966,56252,75650,240043,954050,541
   > Total Current Assets 
0
0
12,549
0
18,931
20,391
31,055
64,026
53,604
43,400
82,649
62,264
100,076
85,129
60,922
128,989
121,490
111,685
106,751
98,478
208,906
199,240
214,257
219,750
229,626
233,100
252,582
248,625
257,989
235,444
243,089
447,964
450,991
365,835
391,110
418,734
455,054
472,049
477,969
508,673
394,609
378,847
408,557
431,594
455,823
658,520
651,623
720,247
792,579
822,352
866,048
667,018
526,210
533,411
498,334
376,114
429,324
447,255
509,994
509,994447,255429,324376,114498,334533,411526,210667,018866,048822,352792,579720,247651,623658,520455,823431,594408,557378,847394,609508,673477,969472,049455,054418,734391,110365,835450,991447,964243,089235,444257,989248,625252,582233,100229,626219,750214,257199,240208,90698,478106,751111,685121,490128,98960,92285,129100,07662,26482,64943,40053,60464,02631,05520,39118,931012,54900
       Cash And Cash Equivalents 
12,386
0
7,077
0
12,353
13,851
26,133
59,331
27,450
16,402
46,168
25,213
21,445
8,709
42,573
26,272
96,954
3,383
12,515
64,573
108,200
17,756
158,167
154,886
32,722
30,522
158,965
35,029
25,309
24,442
35,944
108,970
53,814
26,216
54,126
41,563
116,871
230,941
132,526
215,036
59,737
85,139
78,228
54,589
78,552
125,244
99,957
66,699
105,774
134,036
585,578
226,751
122,061
109,424
104,139
35,545
86,810
99,119
153,298
153,29899,11986,81035,545104,139109,424122,061226,751585,578134,036105,77466,69999,957125,24478,55254,58978,22885,13959,737215,036132,526230,941116,87141,56354,12626,21653,814108,97035,94424,44225,30935,029158,96530,52232,722154,886158,16717,756108,20064,57312,5153,38396,95426,27242,5738,70921,44525,21346,16816,40227,45059,33126,13313,85112,35307,077012,386
       Short-term Investments 
1,182
0
1,216
0
0
2,079
1,314
0
19,755
20,666
29,985
29,617
62,840
58,240
30,924
83,974
87,330
78,464
59,637
45,811
55,660
131,972
119,138
113,989
120,425
115,916
101,981
114,992
137,358
136,686
136,653
274,729
328,628
267,864
257,221
298,225
254,450
155,468
250,928
197,406
232,502
180,505
213,722
263,875
248,240
406,881
421,705
523,364
540,821
559,822
70,831
225,443
194,332
219,301
184,512
138,454
133,956
136,069
125,283
125,283136,069133,956138,454184,512219,301194,332225,44370,831559,822540,821523,364421,705406,881248,240263,875213,722180,505232,502197,406250,928155,468254,450298,225257,221267,864328,628274,729136,653136,686137,358114,992101,981115,916120,425113,989119,138131,97255,66045,81159,63778,46487,33083,97430,92458,24062,84029,61729,98520,66619,75501,3142,079001,21601,182
       Net Receivables 
0
0
1,455
0
3,255
2,531
1,191
1,810
1,055
1,496
2,113
860
3,214
2,459
4,352
5,243
7,756
9,771
14,590
15,969
20,545
20,517
22,366
24,511
24,281
25,919
25,855
25,901
28,651
26,765
29,937
27,702
27,467
27,021
31,658
31,203
35,641
34,266
38,000
39,766
41,147
42,573
47,530
38,988
44,013
46,143
53,046
52,583
68,357
49,975
96,318
92,103
91,105
93,471
98,397
93,205
99,079
96,956
105,556
105,55696,95699,07993,20598,39793,47191,10592,10396,31849,97568,35752,58353,04646,14344,01338,98847,53042,57341,14739,76638,00034,26635,64131,20331,65827,02127,46727,70229,93726,76528,65125,90125,85525,91924,28124,51122,36620,51720,54515,96914,5909,7717,7565,2434,3522,4593,2148602,1131,4961,0551,8101,1912,5313,25501,45500
       Other Current Assets 
1,176
0
2,288
0
2,125
2,959
2,126
1,107
3,460
3,169
3,138
1,496
3,278
3,815
18,349
2,740
2,559
2,486
2,819
2,572
3,139
3,504
4,461
4,089
3,429
4,611
6,117
8,959
5,755
10,075
9,277
6,252
7,480
5,622
6,694
7,700
6,039
6,490
7,946
9,437
8,526
10,392
10,781
14,476
10,067
11,710
12,265
12,995
12,363
11,310
14,771
19,059
18,124
14,416
15,223
15,933
17,349
18,591
21,504
21,50418,59117,34915,93315,22314,41618,12419,05914,77111,31012,36312,99512,26511,71010,06714,47610,78110,3928,5269,4377,9466,4906,0397,7006,6945,6227,4806,2529,27710,0755,7558,9596,1174,6113,4294,0894,4613,5043,1392,5722,8192,4862,5592,74018,3493,8153,2781,4963,1383,1693,4601,1072,1262,9592,12502,28801,176
   > Long-term Assets 
0
0
31,405
0
31,309
32,365
35,507
33,843
33,488
34,209
30,841
32,000
42,777
47,697
51,132
56,252
56,940
60,710
63,069
65,215
83,174
106,154
111,815
115,280
125,367
135,888
137,041
142,581
142,710
145,709
148,377
151,998
154,754
240,255
237,261
203,303
187,627
186,996
211,384
210,483
393,234
428,642
422,508
389,785
410,288
561,749
622,890
567,302
533,254
533,650
1,209,305
1,224,458
1,207,778
1,200,954
1,182,866
1,147,304
1,113,057
1,087,207
1,064,392
1,064,3921,087,2071,113,0571,147,3041,182,8661,200,9541,207,7781,224,4581,209,305533,650533,254567,302622,890561,749410,288389,785422,508428,642393,234210,483211,384186,996187,627203,303237,261240,255154,754151,998148,377145,709142,710142,581137,041135,888125,367115,280111,815106,15483,17465,21563,06960,71056,94056,25251,13247,69742,77732,00030,84134,20933,48833,84335,50732,36531,309031,40500
       Property Plant Equipment 
18,037
0
19,560
0
20,329
21,773
23,950
24,359
24,633
25,825
25,103
26,492
29,966
35,319
39,116
41,130
42,065
45,944
48,182
49,891
53,513
56,148
60,632
67,206
77,809
86,323
90,324
95,846
99,282
100,388
101,016
102,571
103,239
105,947
107,046
109,225
111,276
110,063
108,670
133,737
141,986
140,612
142,805
145,718
191,096
201,574
211,180
217,710
224,554
229,025
264,811
264,038
263,361
263,308
254,389
249,701
246,147
239,177
234,947
234,947239,177246,147249,701254,389263,308263,361264,038264,811229,025224,554217,710211,180201,574191,096145,718142,805140,612141,986133,737108,670110,063111,276109,225107,046105,947103,239102,571101,016100,38899,28295,84690,32486,32377,80967,20660,63256,14853,51349,89148,18245,94442,06541,13039,11635,31929,96626,49225,10325,82524,63324,35923,95021,77320,329019,560018,037
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
7,992
8,109
8,297
8,582
8,980
9,539
10,328
11,327
12,520
22,048
23,761
25,381
27,123
28,888
30,880
32,784
42,751
44,670
46,737
48,829
50,943
52,956
55,197
57,490
59,912
62,040
62,040
62,040
100,538
99,547
99,547
99,547
99,547
99,547
99,547
99,547
99,547
99,547
145,175
145,722
146,132
157,361
163,243
163,243
163,243
163,243
163,243
163,243163,243163,243163,243163,243157,361146,132145,722145,17599,54799,54799,54799,54799,54799,54799,54799,54799,547100,53862,04062,04062,04059,91257,49055,19752,95650,94348,82946,73744,67042,75132,78430,88028,88827,12325,38123,76122,04812,52011,32710,3289,5398,9808,5828,2978,1097,992000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,474
24,527
24,431
19,938
17,941
17,921
13,462
13,470
0
0
0
0
0
80,807
60,047
21,683
1,601
14,146
25,871
14,146
25,362
70,577
64,798
35,120
8,261
44,062
109,478
34,971
17,966
21,192
21,987
35,770
35,812
17,394
64,379
40,566
0
0
2,410
2,4100040,56664,37917,39435,81235,77021,98721,19217,96634,971109,47844,0628,26135,12064,79870,57725,36214,14625,87114,1461,60121,68360,04780,8070000013,47013,46217,92117,94119,93824,43124,52713,47400000000000000000000
       Intangible Assets 
13,084
0
11,178
0
10,045
9,479
8,912
8,346
7,780
7,204
5,259
4,746
4,233
3,721
3,208
2,695
2,183
1,670
1,157
644
564
483
403
323
242
161
81
32,784
42,751
44,670
46,737
48,829
50,943
52,956
55,197
57,490
59,912
62,040
0
0
108,320
106,354
104,387
102,421
100,454
98,487
96,521
94,554
92,588
90,621
623,968
609,646
595,324
581,002
540,546
526,224
511,902
497,580
483,258
483,258497,580511,902526,224540,546581,002595,324609,646623,96890,62192,58894,55496,52198,487100,454102,421104,387106,354108,3200062,04059,91257,49055,19752,95650,94348,82946,73744,67042,75132,784811612423234034835646441,1571,6702,1832,6953,2083,7214,2334,7465,2597,2047,7808,3468,9129,47910,045011,178013,084
       Long-term Assets Other 
0
0
667
0
935
1,113
2,645
1,138
1,075
1,180
479
762
586
548
511
3,845
3,712
3,557
3,402
3,353
3,103
2,948
2,588
2,432
2,252
2,595
2,294
481
677
651
624
598
572
545
825
759
692
747
657
560
17,028
11,552
75,769
6,979
10,930
90,004
74,492
88,941
17,966
21,192
76,410
0
0
26,358
27,170
32,285
101,462
35,547
36,049
36,04935,547101,46232,28527,17026,3580076,41021,19217,96688,94174,49290,00410,9306,97975,76911,55217,0285606577476927598255455725986246516774812,2942,5952,2522,4322,5882,9483,1033,3533,4023,5573,7123,8455115485867624791,1801,0751,1382,6451,113935066700
> Total Liabilities 
43,051
0
66,903
0
84,471
95,794
114,945
66,723
64,157
63,734
65,221
57,022
48,348
52,381
46,199
115,449
119,288
123,277
128,571
127,982
144,111
150,322
154,927
151,009
159,714
159,975
171,231
165,036
172,348
167,005
172,490
329,329
344,697
341,290
348,888
343,516
352,168
357,779
368,127
391,637
446,193
461,327
476,121
447,342
477,963
635,579
654,825
636,731
638,665
637,400
1,344,945
1,181,900
977,352
964,242
906,190
755,377
734,406
702,911
704,256
704,256702,911734,406755,377906,190964,242977,3521,181,9001,344,945637,400638,665636,731654,825635,579477,963447,342476,121461,327446,193391,637368,127357,779352,168343,516348,888341,290344,697329,329172,490167,005172,348165,036171,231159,975159,714151,009154,927150,322144,111127,982128,571123,277119,288115,44946,19952,38148,34857,02265,22163,73464,15766,723114,94595,79484,471066,903043,051
   > Total Current Liabilities 
17,016
0
14,417
0
14,141
13,806
16,322
19,663
17,479
17,829
31,911
19,158
15,236
19,828
14,156
12,698
15,835
116,972
121,943
121,587
129,506
135,223
140,010
136,453
145,472
145,411
151,676
146,139
150,438
146,831
44,838
45,648
57,510
52,337
56,217
48,368
53,024
54,523
60,661
58,991
83,004
95,838
107,673
80,313
70,583
86,272
253,328
232,084
228,693
225,788
521,118
305,073
133,179
131,526
147,774
98,698
108,912
93,661
97,383
97,38393,661108,91298,698147,774131,526133,179305,073521,118225,788228,693232,084253,32886,27270,58380,313107,67395,83883,00458,99160,66154,52353,02448,36856,21752,33757,51045,64844,838146,831150,438146,139151,676145,411145,472136,453140,010135,223129,506121,587121,943116,97215,83512,69814,15619,82815,23619,15831,91117,82917,47919,66316,32213,80614,141014,417017,016
       Short-term Debt 
0
0
3,478
0
3,416
1,645
3,182
5,568
6,328
4,871
8,258
2,585
9,279
837
9,792
9,872
12,260
97,927
98,961
99,996
101,031
102,065
103,100
104,135
103,885
104,907
105,928
105,215
106,388
107,563
108,738
759
319
320
324
327
330
334
338
5,583
6,172
5,043
4,935
3,968
7,620
7,455
157,073
157,150
159,325
161,630
382,591
201,698
41,910
42,236
42,769
19,804
28,485
17,266
17,442
17,44217,26628,48519,80442,76942,23641,910201,698382,591161,630159,325157,150157,0737,4557,6203,9684,9355,0436,1725,583338334330327324320319759108,738107,563106,388105,215105,928104,907103,885104,135103,100102,065101,03199,99698,96197,92712,2609,8729,7928379,2792,5858,2584,8716,3285,5683,1821,6453,41603,47800
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
276
0
0
0
104,040
0
106,388
107,563
108,738
759
269,647
320
324
327
330
334
338
5,583
0
0
0
0
0
0
149,648
151,647
153,681
155,751
374,700
193,680
33,776
33,872
33,648
10,853
19,504
8,641
8,641
8,6418,64119,50410,85333,64833,87233,776193,680374,700155,751153,681151,647149,6480000005,583338334330327324320269,647759108,738107,563106,3880104,0400002760000000000000000000000
       Accounts payable 
11,794
0
6,994
0
6,522
7,015
6,038
6,097
5,052
4,313
3,440
2,302
440
4,789
2,569
1,001
1,712
1,559
3,069
2,605
3,145
7,747
6,758
5,565
13,299
8,471
8,739
10,484
4,614
7,287
7,511
9,373
10,392
12,278
14,658
14,913
14,260
13,795
14,368
13,369
13,347
16,064
12,799
15,850
9,160
13,008
10,431
9,110
12,179
7,895
10,543
14,843
13,983
12,933
15,220
17,261
24,206
16,511
15,698
15,69816,51124,20617,26115,22012,93313,98314,84310,5437,89512,1799,11010,43113,0089,16015,85012,79916,06413,34713,36914,36813,79514,26014,91314,65812,27810,3929,3737,5117,2874,61410,4848,7398,47113,2995,5656,7587,7473,1452,6053,0691,5591,7121,0012,5694,7894402,3023,4404,3135,0526,0976,0387,0156,52206,994011,794
       Other Current Liabilities 
3,779
0
1,599
0
2,019
2,984
4,835
5,448
3,641
6,291
7,159
7,040
1,164
13,036
823
853
891
16,514
18,905
17,978
23,904
23,985
28,726
25,327
26,862
30,607
35,583
29,165
38,388
31,159
36,732
34,996
46,799
39,739
41,133
111
38,434
35
45,955
45,622
11,500
13,591
18,179
14,041
4,504
5,406
14,736
14,864
5,026
5,070
117,859
78,407
77,286
76,357
89,785
61,633
64,862
68,525
64,243
64,24368,52564,86261,63389,78576,35777,28678,407117,8595,0705,02614,86414,7365,4064,50414,04118,17913,59111,50045,62245,9553538,43411141,13339,73946,79934,99636,73231,15938,38829,16535,58330,60726,86225,32728,72623,98523,90417,97818,90516,51489185382313,0361,1647,0407,1596,2913,6415,4484,8352,9842,01901,59903,779
   > Long-term Liabilities 
0
0
52,486
0
70,330
81,988
98,623
47,060
46,678
45,905
33,310
37,864
33,112
32,553
32,043
102,751
103,453
6,305
6,628
6,395
14,605
15,099
14,917
14,556
14,242
14,564
19,555
18,897
21,910
20,174
127,652
283,681
287,187
288,953
292,671
295,148
299,144
303,256
307,466
332,646
363,189
365,489
368,448
367,029
407,380
549,307
401,497
404,647
409,972
411,612
823,827
876,827
844,173
832,716
758,416
656,679
625,494
609,250
606,873
606,873609,250625,494656,679758,416832,716844,173876,827823,827411,612409,972404,647401,497549,307407,380367,029368,448365,489363,189332,646307,466303,256299,144295,148292,671288,953287,187283,681127,65220,17421,91018,89719,55514,56414,24214,55614,91715,09914,6056,3956,6286,305103,453102,75132,04332,55333,11237,86433,31045,90546,67847,06098,62381,98870,330052,48600
       Long term Debt Total 
0
0
0
0
0
0
0
0
20,358
20,603
18,537
23,632
24,670
24,930
25,191
95,857
96,892
0
0
0
0
0
0
0
0
0
0
0
0
0
108,738
265,992
269,328
272,721
276,173
279,685
283,258
286,893
290,592
294,356
298,185
302,081
306,045
310,078
314,182
456,464
313,030
317,338
321,708
326,146
0
326,828
318,344
713,999
0
542,918
532,183
0
0
00532,183542,9180713,999318,344326,8280326,146321,708317,338313,030456,464314,182310,078306,045302,081298,185294,356290,592286,893283,258279,685276,173272,721269,328265,992108,738000000000000096,89295,85725,19124,93024,67023,63218,53720,60320,35800000000
       Capital Lease Obligations Min Short Term Debt
0
0
-3,478
0
-3,416
-1,645
-3,182
-5,568
-6,328
-4,871
-8,258
-2,585
-9,279
-837
-9,792
-9,872
-12,260
-97,927
-98,961
-99,996
-101,031
-102,065
-103,100
-104,135
-103,885
-104,907
-105,928
-105,215
-106,388
-107,563
-108,738
-759
-319
-320
-324
-327
-330
-334
-338
29,297
39,041
38,882
40,938
40,189
73,888
72,448
-78,623
-81,981
-85,446
-88,967
-302,973
-123,970
33,799
31,529
31,154
51,589
40,542
48,448
46,165
46,16548,44840,54251,58931,15431,52933,799-123,970-302,973-88,967-85,446-81,981-78,62372,44873,88840,18940,93838,88239,04129,297-338-334-330-327-324-320-319-759-108,738-107,563-106,388-105,215-105,928-104,907-103,885-104,135-103,100-102,065-101,031-99,996-98,961-97,927-12,260-9,872-9,792-837-9,279-2,585-8,258-4,871-6,328-5,568-3,182-1,645-3,4160-3,47800
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
6,554
7,455
6,357
6,159
3,808
3,280
3,132
3,417
3,327
3,314
3,416
3,435
4,384
5,235
5,409
5,404
5,447
6,125
11,473
11,020
14,163
12,557
11,427
10,332
17,859
16,232
16,498
15,463
15,886
16,363
16,874
38,290
65,004
63,408
62,403
56,951
93,198
92,843
88,467
87,309
20,029
85,466
67,445
66,652
35,247
118,717
37,791
51,319
93,311
36,220
38,271
38,27136,22093,31151,31937,791118,71735,24766,65267,44585,46620,02987,30988,46792,84393,19856,95162,40363,40865,00438,29016,87416,36315,88615,46316,49816,23217,85910,33211,42712,55714,16311,02011,4736,1255,4475,4045,4095,2354,3843,4353,4163,3143,3273,4173,1323,2803,8086,1596,3577,4556,55400000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
17,847
8,416
8,073
4,634
4,343
3,720
3,477
3,234
2,991
3,212
2,960
10,221
9,864
9,508
9,152
8,795
8,439
8,082
7,877
7,747
7,617
7,487
7,357
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000007,3577,4877,6177,7477,8778,0828,4398,7959,1529,5089,86410,2212,9603,2122,9913,2343,4773,7204,3434,6348,0738,41617,847000000000
> Total Stockholder Equity
7,490
0
-22,949
0
-34,231
-43,038
-48,383
31,146
22,935
13,875
48,269
37,242
94,505
80,445
65,855
69,792
59,142
49,118
41,249
35,711
147,969
155,072
171,145
184,021
195,279
209,013
218,392
226,170
228,351
214,148
218,976
270,633
261,048
264,800
279,483
278,521
290,513
301,266
321,226
327,519
341,650
346,162
354,944
374,037
388,148
584,690
619,688
650,818
687,168
718,602
730,408
709,576
756,636
770,123
775,010
768,041
807,975
831,551
870,130
870,130831,551807,975768,041775,010770,123756,636709,576730,408718,602687,168650,818619,688584,690388,148374,037354,944346,162341,650327,519321,226301,266290,513278,521279,483264,800261,048270,633218,976214,148228,351226,170218,392209,013195,279184,021171,145155,072147,96935,71141,24949,11859,14269,79265,85580,44594,50537,24248,26913,87522,93531,146-48,383-43,038-34,2310-22,94907,490
   Common Stock
1
0
1
0
6
1
1
17
17
17
25
25
32
32
33
33
33
34
34
34
36
36
36
36
37
37
37
37
37
37
37
40
40
41
41
41
41
41
41
41
42
42
42
42
43
43
44
44
44
45
45
45
46
46
46
46
46
46
46
464646464646464545454444444343424242424141414141414140403737373737373736363636343434333333323225251717171160101
   Retained Earnings Total Equity00-142,524-168,2870-138,649-137,956-157,832-211,895-206,765-224,425-243,506-253,875-268,390-398,509-391,239-399,398-394,510-388,423-391,153-388,226-396,511-395,871-398,455-389,136-393,731-386,134-366,391-346,238-342,266-320,101-312,143-308,289-305,791-308,877-308,885-310,145-315,947-312,943-307,906-296,429-284,473-269,689-255,658-232,520-216,174-200,429-192,133-180,239-164,956-155,44800000000
   Accumulated Other Comprehensive Income 
0
0
-4,594
0
0
0
-6,066
-6,490
-6,918
-5
15
17
98
64
27
44
13
17
5
5
-31
8
-80
-28
-27
-29
-52
49
138
-28
-30
-82
-64
-67
-454
-901
-545
-241
-280
182
500
447
322
-1,046
1,490
847
318
172
181
153
167
-527
-605
-670
-380
-137
-173
-10
247
247-10-173-137-380-670-605-5271671531811723188471,490-1,046322447500182-280-241-545-901-454-67-64-82-30-2813849-52-29-27-28-808-31551713442764981715-5-6,918-6,490-6,066000-4,59400
   Capital Surplus 
0
0
0
0
0
0
0
0
178,368
178,821
228,470
229,335
294,806
296,525
298,317
325,375
328,787
333,542
337,639
343,578
460,907
470,975
481,334
492,898
504,146
514,796
526,696
538,227
548,277
556,405
565,207
637,066
647,206
658,557
669,032
677,836
686,888
697,977
709,691
718,449
729,531
740,183
753,978
766,280
785,124
852,190
873,201
894,108
911,368
925,169
942,091
867,890
895,151
909,396
0
936,419
950,626
0
0
00950,626936,4190909,396895,151867,890942,091925,169911,368894,108873,201852,190785,124766,280753,978740,183729,531718,449709,691697,977686,888677,836669,032658,557647,206637,066565,207556,405548,277538,227526,696514,796504,146492,898481,334470,975460,907343,578337,639333,542328,787325,375298,317296,525294,806229,335228,470178,821178,36800000000
   Treasury Stock00000000000000000000000000000000000000000-2-2-2-2-2-2-2-2-2-2-2-2-200000
   Other Stockholders Equity 
0
0
91,400
0
86,751
86,822
94,587
184,305
185,284
186,164
236,765
238,493
305,043
307,633
309,945
336,901
339,369
344,946
350,220
358,169
476,200
488,474
501,368
515,647
529,598
539,869
551,561
566,273
579,625
590,865
602,687
677,596
689,798
704,040
717,788
677,935
687,343
755,243
770,969
783,789
729,031
812,898
829,740
766,234
785,124
852,190
873,201
894,108
911,368
925,169
942,091
867,890
895,151
909,396
924,095
936,419
807,975
963,181
976,633
976,633963,181807,975936,419924,095909,396895,151867,890942,091925,169911,368894,108873,201852,190785,124766,234829,740812,898729,031783,789770,969755,243687,343677,935717,788704,040689,798677,596602,687590,865579,625566,273551,561539,869529,598515,647501,368488,474476,200358,169350,220344,946339,369336,901309,945307,633305,043238,493236,765186,164185,284184,30594,58786,82286,751091,40000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue674,978
Cost of Revenue-241,957
Gross Profit433,021433,021
 
Operating Income (+$)
Gross Profit433,021
Operating Expense-345,698
Operating Income87,32387,323
 
Operating Expense (+$)
Research Development76,257
Selling General Administrative116,401
Selling And Marketing Expenses153,040
Operating Expense345,698345,698
 
Net Interest Income (+$)
Interest Income10,804
Interest Expense-23,806
Other Finance Cost-4,153
Net Interest Income-17,155
 
Pretax Income (+$)
Operating Income87,323
Net Interest Income-17,155
Other Non-Operating Income Expenses0
Income Before Tax (EBT)61,701112,945
EBIT - interestExpense = 63,517
61,701
65,761
Interest Expense23,806
Earnings Before Interest and Taxes (EBIT)87,32385,507
Earnings Before Interest and Taxes (EBITDA)162,897
 
After tax Income (+$)
Income Before Tax61,701
Tax Provision-2,930
Net Income From Continuing Ops6,98358,771
Net Income41,955
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses587,655
Total Other Income/Expenses Net-25,62217,155
 

Technical Analysis of Pacira
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Pacira. The general trend of Pacira is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Pacira's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Pacira Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 27.10 < 27.37 < 27.89.

The bearish price targets are: 25.93.

Tweet this
Pacira Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Pacira Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Pacira Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Pacira Pharmaceuticals Inc. The current macd is -0.82772833.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Pacira price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Pacira. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Pacira price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Pacira Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartPacira Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Pacira Pharmaceuticals Inc. The current adx is 29.39.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Pacira shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Pacira Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Pacira Pharmaceuticals Inc. The current sar is 27.69.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Pacira Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Pacira Pharmaceuticals Inc. The current rsi is 30.63. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Pacira Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartPacira Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Pacira Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Pacira price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Pacira Pharmaceuticals Inc Daily Stochastic Oscillator ChartPacira Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Pacira Pharmaceuticals Inc. The current cci is -146.0102255.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Pacira Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartPacira Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Pacira Pharmaceuticals Inc. The current cmo is -49.63329516.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Pacira Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartPacira Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Pacira Pharmaceuticals Inc. The current willr is -90.83557951.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Pacira Pharmaceuticals Inc Daily Williams %R ChartPacira Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Pacira Pharmaceuticals Inc.

Pacira Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Pacira Pharmaceuticals Inc. The current atr is 0.95484384.

Pacira Pharmaceuticals Inc Daily Average True Range (ATR) ChartPacira Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Pacira Pharmaceuticals Inc. The current obv is -11,124,010.

Pacira Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartPacira Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Pacira Pharmaceuticals Inc. The current mfi is 27.84.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Pacira Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartPacira Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Pacira Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.

6.3. Candlestick Patterns

Pacira Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Pacira Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5030.635
Ma 20Greater thanMa 5028.124
Ma 50Greater thanMa 10029.048
Ma 100Greater thanMa 20030.101
OpenGreater thanClose26.790
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Pacira with someone you think should read this too:
  • Are you bullish or bearish on Pacira? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Pacira? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Pacira Pharmaceuticals Inc

I send you an email if I find something interesting about Pacira Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Pacira Pharmaceuticals Inc.

Receive notifications about Pacira Pharmaceuticals Inc in your mailbox!